A practical reference on MC4R: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-09 and is reviewed periodically as new material appears.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
| Property | Value | Notes |
|---|---|---|
| Storage form | Lyophilized powder | Longer stability at -20 °C |
| Reconstitution solvent | Sterile water or buffer | Depends on intended application |
| Purity assessment | Reverse-phase HPLC | Reported as peak area percentage |
| Identity confirmation | Mass spectrometry | Compared against theoretical mass |
| Main stability concern | Repeated freeze-thaw | May promote aggregation |
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
== Further reading == Müller, Bodo (2006). Coatings formulation: an international textbook. Urlich Poth. Hannover: Vincentz. ISBN 3-87870-177-2. OCLC 76886114. Spyrou, Emmanouil (2012). Powder coatings chemistry and technology (3 ed.). Vincentz Network. ISBN 978-3-86630-884-8. OCLC 828194496. Titanium and titanium alloys, edited by C. Leyens and M. Peters, Wiley-VCH, ISBN 3-527-30534-3, table 6.2: overview of several coating systems and fabrication processes for titanium alloys and titanium aluminides (amended) Coating Materials for Electronic Applications: Polymers, Processes, Reliability, Testing by James J. Licari; William Andrew Publishing, Elsevier, ISBN 0-8155-1492-1 High-Performance Organic Coatings, ed. AS Khanna, Elsevier BV, 2015, ISBN 978-1-84569-265-0
==== Other uses in biology, medicine, and chemistry ==== Abdominal aortic aneurysm Acral acanthotic anomaly In the initialism OPQRST-AAA, aggravating/alleviating factors, associated symptoms, and attributions/adaptations Cavaticovelia aaa (aaa water treader), an insect from Hawaii, named after ʻaʻaʻā, the Hawaiian word for "lava tube" List of banana cultivars § AAA Group, triploid Musa acuminata
The third generation of the Familia Presto was announced in September 1973, a month before the 1973 oil crisis. It was basically an updated version of the 1970 Familia Presto, reintroduced with 60 mm wider bodywork and reworked front and rear designs. It was promoted and marketed as the "Widebody" in Japan. These changes were made only to the saloons and coupé, while the van/wagon and pickups remained in production and retaining the original narrower bodywork with minor changes. The Familia Presto continued using the "Mazda 1000/1300" name in most export markets, "Mazda Marella" name was also retained in Finland. The Rotary Presto saloon/coupé was discontinued in Japan, having been replaced by the larger Grand Familia-based Mazda Savannah. The piston-engined 1000/1300 and rotary-engined R100 coupés were also replaced by 808/818/RX-3 coupé for export market. This generation was not available in North America and replaced by the bigger 808/Mizer/RX-3. Developed to meet new stricter emissions standards in the domestic market, the Presto featured the 1272 cc TC engine or the by now familiar, pushrod 1.0-litre PB unit. Power outputs in Japan (JIS gross) are 62 PS (46 kW; 61 hp) and 87 PS (64 kW; 86 hp) respectively, 50 PS (37 kW; 49 hp) and 66 PS (49 kW; 65 hp) (DIN) for export markets. Production of the third generation Familia ended in January 1977, but not before another minor facelift and emissions scrubbing had taken place in February 1976. This changes were not applied for export market.
After hypothyroidism was found to cause a lower basal metabolic rate, this was used as a marker to guide adjustments in therapy in the early 20th century (around 1915). However, a low basal metabolic rate was known to be non-specific, also present in malnutrition. The first laboratory test to help assess thyroid status was the serum protein-bound iodine, which came into use around the 1950s. In 1971, the thyroid stimulating hormone (TSH) radioimmunoassay was developed, which was the most specific marker for assessing thyroid status in patients. Many people who were being treated based on basal metabolic rate, minimizing hypothyroid symptoms, or based on serum protein-bound iodine, were found to have excessive thyroid hormone. The following year, in 1972, a T3 radioimmunoassay was developed, and in 1974, a T4 radioimmunoassay was developed.
Sources: en.wikipedia.org
In 1936, Florey received a letter from Hilda stating that their mother Bertha had terminal cancer, so he arranged to travel to Australia with Ethel, Paquita and Charles during the summer break. They travelled on the SS Orsova to Melbourne, where they were met by Bertha, Charlotte, Hilda, Valetta and Hilda's daughter Joan Gardner. In addition to spending time with his family, he visited Peter MacCallum at his laboratory. MacCallum introduced Florey to Roy Douglas (Pansy) Wright, an experimental physiologist, and they arranged for Wright to come to Oxford the following year to assist Florey and Jennings with their work on mucus secretion. Florey then joined Ethel and the children in Adelaide. The family returned to Oxford in October. Bertha died on 27 November. Henceforth, Florey would lead an interdisciplinary team in an attack on a particular problem. Each member of the team tackled a particular aspect in their own way, with simultaneous research along different lines building up a complete picture. This was a manner of collaboration that was practically unknown in the UK at the time. However, the team members, including Florey, all worked on multiple projects at the same time. Florey was strict with his own collaborators, but gave considerable latitude to those working on other aspects of a project. He did not hold team meetings, although he encouraged team members to discuss issues with himself and each other, and he dropped by each laboratory nearly every day to view progress and provide suggestions. The first such project was an investigation of lymphocytes.
In addition to regulating the experiments that were conducted, the guidelines also forbade the performance of other experiments. One such experiment was the cloning of recombinant DNAs derived from highly pathogenic organisms. In addition, neither the cloning of DNA containing toxin genes nor large-scale experiments using recombinant DNAs that were able to make products that were potentially harmful to humans, animals, or plants were allowed under the guidelines. These experiments were banned because the potential biohazards could not be contained by the then-current safety precautions.
In February of 2025 the first case of CRISPR gene editing therapy on a child was documented. It was used to treat Severe Carbamoyl Phosphate Synthetase 1 Deficiency. It was administered At Children's Hospital of Philadelphia and is currently successful in its use to counteract the disease. "Advanced Gene Editing: CRISPR-Cas9" (PDF). Congressional Research Service. Archived from the original (PDF) on 5 December 2017. Retrieved 24 October 2017. "Jennifer Doudna talk: Genome Engineering with CRISPR-Cas9: Birth of a Breakthrough Technology". 10 September 2022. Archived from the original on 25 November 2016. Retrieved 24 November 2016. "Human Nature". NOVA. Season 47. Episode 9. 9 September 2020. PBS. WGBH. Retrieved 7 April 2023.
ADLM (formerly the American Association for Clinical Chemistry) supports expanding and encouraging consumers' ability to access their own health information by allowing individuals to directly order their own laboratory tests. Key positions include: only reputable CLIA-certified laboratories should perform DTC testing; laboratories must validate all sample collection, processing, and testing practices per CLIA regulations; transparent, understandable information must be provided regarding clinical indications, specimen collection, results interpretation, and cost. ASCP believes that it is important for physicians and patients to use the test results as a mechanism to discuss a variety of health topics. Key ASCP recommendations include: laboratories should follow applicable state laws regarding direct access testing; laboratories should inform patients about restrictions in insurance and medical coverage; patients should consult with their primary care physician whenever possible after receiving DAT test results.
24496Cm + 126C → 256102No* → 252102No + 4 10n Meanwhile, in Dubna, experiments were carried out in 1958 and 1960 aiming to synthesize element 102 as well. The first 1958 experiment bombarded 239Pu and 241Pu with 16O ions. Some alpha decays with energies just over 8.5 MeV were observed, and they were assigned to 251,252,253No, although the team wrote that formation of isotopes from lead or bismuth impurities (which would not produce nobelium) could not be ruled out. While later 1958 experiments noted that new isotopes could be produced from mercury, thallium, lead, or bismuth impurities, the scientists still stood by their conclusion that element 102 could be produced from this reaction, mentioning a half-life of under 30 seconds and a decay energy of (8.8 ± 0.5) MeV. Later 1960 experiments proved that these were background effects. 1967 experiments also lowered the decay energy to (8.6 ± 0.4) MeV, but both values are too high to possibly match those of 253No or 254No. The Dubna team later stated in 1970 and again in 1987 that these results were not conclusive. In 1961, Berkeley scientists claimed the discovery of lawrencium in the reaction of californium with boron and carbon ions. They claimed the production of the isotope 257Lr, and also claimed to have synthesized an alpha-decaying isotope of element 102 that had a half-life of 15 s and alpha decay energy 8.2 MeV. They assigned this to 255No without giving a reason for the assignment.
Sources: en.wikipedia.org
Three studies report specifications and results of the largest cosmological simulations that incorporate both dark matter and normal matter, further deepening the S8 tension challenge to the standard cosmological model.
===== Iguania ===== Clade Acrodonta Family Agamidae Pogona vitticeps, Central bearded dragon, (2015) Clade Pleurodonta Family Dactyloidae Anolis carolinensis, Carolina anole, (2011) Family Phrynosomatidae Phrynosoma platyrhinos, Dessert horned lizard, (2021) Phrynosoma cornutum, Texas horned lizard, (2021) Sceloporus undulatus, Eastern fence lizard (2021)
Laboratory informatics is the specialized application of information technology aimed at optimizing and extending laboratory operations. It encompasses data acquisition (e.g. through sensors and hardware or voice), instrument interfacing, laboratory networking, data processing, specialized data management systems (such as a chromatography data system), a laboratory information management system, scientific data management (including data mining and data warehousing), and knowledge management (including the use of an electronic lab notebook). It has become more prevalent with the rise of other "informatics" disciplines such as bioinformatics, cheminformatics and health informatics. Several graduate programs are focused on some form of laboratory informatics, often with a clinical emphasis. A closely related - some consider subsuming - field is laboratory automation.
== Mechanism of action == Prazepam exerts its therapeutic effects primarily via modulating the benzodiazepine site which in turn enhances GABA function in the brain. Prazepam like other benzodiazepines has anticonvulsant properties, but its anticonvulsant properties are not as potent as other benzodiazepines when tested in animal studies.
additive (the result is simply the expected effect of each drug taken independently), synergistic (combining the drugs leads to a larger effect than expected), or antagonistic (combining the drugs leads to a smaller effect than expected). It may be difficult to distinguish between synergistic or additive interactions, as individual effects of drugs may vary. Direct interactions between drugs are also possible and may occur when two drugs are mixed before intravenous injection. For example, mixing thiopentone and suxamethonium can lead to the precipitation of thiopentone.
Sources: en.wikipedia.org
Storage at -20 °C or below is standard for long-term stability. Desiccant and sealed containers limit moisture exposure. Solutions are prepared only when needed.
Reverse-phase HPLC separates components by hydrophobicity and reports purity as a percentage of total peak area. It does not by itself confirm molecular identity. Mass spectrometry is used alongside it for that purpose.
They link a specific lot to its analytical results and storage history. This traceability supports reproducibility when results differ between experiments. Records also help identify when re-testing is warranted.
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.